OBJECTIVE: Little information is available regarding current practice in continuous renal replacement therapy (CRRT) for the treatment of acute renal failure (ARF) and the possible clinical effect of practice variation. DESIGN: Prospective observational study. SETTING: A total of 54 intensive care units (ICUs) in 23 countries. PATIENTS AND PARTICIPANTS: A cohort of 1006 ICU patients treated with CRRT for ARF. INTERVENTIONS: Collection of demographic, clinical and outcome data. MEASUREMENTS AND RESULTS: All patients except one were treated with venovenous circuits, most commonly as venovenous hemofiltration (52.8%). Approximately one-third received CRRT without anticoagulation (33.1%). Among patients who received anticoagulation, unfractionated heparin (UFH) was the most common choice (42.9%), followed by sodium citrate (9.9%), nafamostat mesilate (6.1%), and low-molecular-weight heparin (LMWH; 4.4%). Hypotension related to CRRT occurred in 19% of patients and arrhythmias in 4.3%. Bleeding complications occurred in 3.3% of patients. Treatment with LMWH was associated with a higher incidence of bleeding complications (11.4%) compared to UFH (2.3%, p = 0.0083) and citrate (2.0%, p = 0.029). The median dose of CRRT was 20.4 ml/kg/h. Only 11.7% of patients received a dose of > 35 ml/kg/h. Most (85.5%) survivors recovered to dialysis independence at hospital discharge. Hospital mortality was 63.8%. Multivariable analysis showed that no CRRT-related variables (mode, filter material, drug for anticoagulation, and prescribed dose) predicted hospital mortality. CONCLUSIONS: This study supports the notion that, worldwide, CRRT practice is quite variable and not aligned with best evidence.
OBJECTIVE: Little information is available regarding current practice in continuous renal replacement therapy (CRRT) for the treatment of acute renal failure (ARF) and the possible clinical effect of practice variation. DESIGN: Prospective observational study. SETTING: A total of 54 intensive care units (ICUs) in 23 countries. PATIENTS AND PARTICIPANTS: A cohort of 1006 ICU patients treated with CRRT for ARF. INTERVENTIONS: Collection of demographic, clinical and outcome data. MEASUREMENTS AND RESULTS: All patients except one were treated with venovenous circuits, most commonly as venovenous hemofiltration (52.8%). Approximately one-third received CRRT without anticoagulation (33.1%). Among patients who received anticoagulation, unfractionated heparin (UFH) was the most common choice (42.9%), followed by sodium citrate (9.9%), nafamostat mesilate (6.1%), and low-molecular-weight heparin (LMWH; 4.4%). Hypotension related to CRRT occurred in 19% of patients and arrhythmias in 4.3%. Bleeding complications occurred in 3.3% of patients. Treatment with LMWH was associated with a higher incidence of bleeding complications (11.4%) compared to UFH (2.3%, p = 0.0083) and citrate (2.0%, p = 0.029). The median dose of CRRT was 20.4 ml/kg/h. Only 11.7% of patients received a dose of > 35 ml/kg/h. Most (85.5%) survivors recovered to dialysis independence at hospital discharge. Hospital mortality was 63.8%. Multivariable analysis showed that no CRRT-related variables (mode, filter material, drug for anticoagulation, and prescribed dose) predicted hospital mortality. CONCLUSIONS: This study supports the notion that, worldwide, CRRT practice is quite variable and not aligned with best evidence.
Authors: B K Krämer; A Pickert; C Hohmann; H M Liebich; G A Müller; M Hablitzel; T Risler Journal: Int J Artif Organs Date: 1992-07 Impact factor: 1.595
Authors: K Gastaldello; C Melot; R J Kahn; J L Vanherweghem; J L Vincent; C Tielemans Journal: Nephrol Dial Transplant Date: 2000-02 Impact factor: 5.992
Authors: A Jörres; G M Gahl; C Dobis; M H Polenakovic; K Cakalaroski; B Rutkowski; E Kisielnicka; D H Krieter; K W Rumpf; C Guenther; W Gaus; J Hoegel Journal: Lancet Date: 1999-10-16 Impact factor: 79.321
Authors: V Schwenger; D Kindgen-Milles; C Willam; A Jörres; W Druml; D Czock; S J Klein; M Oppert; M Schmitz; J T Kielstein; A Zarbock; M Joannidis; S John Journal: Med Klin Intensivmed Notfmed Date: 2018-03-15 Impact factor: 0.840